MA52495A - Nouveau traitement de maladies pulmonaires interstitielles - Google Patents
Nouveau traitement de maladies pulmonaires interstitiellesInfo
- Publication number
- MA52495A MA52495A MA052495A MA52495A MA52495A MA 52495 A MA52495 A MA 52495A MA 052495 A MA052495 A MA 052495A MA 52495 A MA52495 A MA 52495A MA 52495 A MA52495 A MA 52495A
- Authority
- MA
- Morocco
- Prior art keywords
- new treatment
- pulmonary diseases
- interstitial pulmonary
- interstitial
- diseases
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5115—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/695—Silicon compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Inorganic Chemistry (AREA)
- Otolaryngology (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1807286.8A GB201807286D0 (en) | 2018-05-03 | 2018-05-03 | New use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA52495A true MA52495A (fr) | 2021-03-10 |
Family
ID=62598220
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA052495A MA52495A (fr) | 2018-05-03 | 2019-05-03 | Nouveau traitement de maladies pulmonaires interstitielles |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20210236425A1 (fr) |
| EP (1) | EP3787599A1 (fr) |
| JP (1) | JP2021522352A (fr) |
| KR (1) | KR20210003779A (fr) |
| CN (1) | CN112469395A (fr) |
| AU (1) | AU2019263701A1 (fr) |
| BR (1) | BR112020022363A2 (fr) |
| CA (1) | CA3099008A1 (fr) |
| EA (1) | EA202092396A1 (fr) |
| GB (1) | GB201807286D0 (fr) |
| MA (1) | MA52495A (fr) |
| MX (1) | MX2020011474A (fr) |
| SG (1) | SG11202010585WA (fr) |
| WO (1) | WO2019211624A1 (fr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201916121D0 (en) | 2019-11-06 | 2019-12-18 | Vicore Pharma Ab | New compositions |
| GB201916130D0 (en) | 2019-11-06 | 2019-12-18 | Vicore Pharma Ab | New compositions |
| GB201916122D0 (en) | 2019-11-06 | 2019-12-18 | Nanologica Ab | New compositions |
| GB201916117D0 (en) | 2019-11-06 | 2019-12-18 | Vicore Pharma Ab | New compositions |
| GB202012152D0 (en) | 2020-08-05 | 2020-09-16 | Vicore Pharma Ab | New compositions |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6254854B1 (en) | 1996-05-24 | 2001-07-03 | The Penn Research Foundation | Porous particles for deep lung delivery |
| EP1313502A4 (fr) * | 2000-08-18 | 2005-10-19 | Medimmune Inc | Methode d'administration d'une proteine fimh en tant que vaccin contre les infections de infections urinaires |
| GB0118689D0 (en) | 2001-08-01 | 2001-09-19 | Psimedica Ltd | Pharmaceutical formulation |
| US20030166509A1 (en) | 2001-11-20 | 2003-09-04 | Advanced Inhalation Research, Inc. | Compositions for sustained action product delivery and methods of use thereof |
| US20070281036A1 (en) * | 2005-12-19 | 2007-12-06 | University Of Vermont And State Agricultural College | System and method of delivering a desired material to a cell |
| AU2011303849A1 (en) | 2010-09-14 | 2013-04-04 | Nanologica Ab | Super-saturating delivery vehicles for poorly water-soluble pharmaceutical and cosmetic active ingredients |
| EP2948148B1 (fr) * | 2013-01-28 | 2020-07-29 | Incozen Therapeutics Pvt. Ltd. | Methodes pour le traitement de maladies autoimmunes, respiratoires et inflammatoires par inhalation de n-oxide de roflumilast |
| US20160090603A1 (en) * | 2014-09-30 | 2016-03-31 | Sandia Corporation | Delivery platforms for the domestication of algae and plants |
| US10507204B2 (en) | 2014-12-19 | 2019-12-17 | Synthon B.V. | Pharmaceutical composition comprising amorphous lenalidomide |
-
2018
- 2018-05-03 GB GBGB1807286.8A patent/GB201807286D0/en not_active Ceased
-
2019
- 2019-05-03 KR KR1020207031807A patent/KR20210003779A/ko unknown
- 2019-05-03 SG SG11202010585WA patent/SG11202010585WA/en unknown
- 2019-05-03 CA CA3099008A patent/CA3099008A1/fr not_active Abandoned
- 2019-05-03 JP JP2021510552A patent/JP2021522352A/ja active Pending
- 2019-05-03 MA MA052495A patent/MA52495A/fr unknown
- 2019-05-03 WO PCT/GB2019/051237 patent/WO2019211624A1/fr unknown
- 2019-05-03 EA EA202092396A patent/EA202092396A1/ru unknown
- 2019-05-03 MX MX2020011474A patent/MX2020011474A/es unknown
- 2019-05-03 US US17/052,649 patent/US20210236425A1/en not_active Abandoned
- 2019-05-03 BR BR112020022363-8A patent/BR112020022363A2/pt not_active Application Discontinuation
- 2019-05-03 EP EP19724894.1A patent/EP3787599A1/fr not_active Withdrawn
- 2019-05-03 CN CN201980029171.8A patent/CN112469395A/zh active Pending
- 2019-05-03 AU AU2019263701A patent/AU2019263701A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR20210003779A (ko) | 2021-01-12 |
| JP2021522352A (ja) | 2021-08-30 |
| GB201807286D0 (en) | 2018-06-20 |
| BR112020022363A2 (pt) | 2021-02-02 |
| EP3787599A1 (fr) | 2021-03-10 |
| CN112469395A (zh) | 2021-03-09 |
| US20210236425A1 (en) | 2021-08-05 |
| WO2019211624A1 (fr) | 2019-11-07 |
| CA3099008A1 (fr) | 2019-11-07 |
| SG11202010585WA (en) | 2020-11-27 |
| EA202092396A1 (ru) | 2021-05-21 |
| MX2020011474A (es) | 2021-02-18 |
| AU2019263701A1 (en) | 2020-11-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA52495A (fr) | Nouveau traitement de maladies pulmonaires interstitielles | |
| IL262608A (en) | Combined treatment of eye disorders and inflammatory diseases | |
| IL276383A (en) | Treatment of ophthalmological diseases | |
| EP3777830C0 (fr) | Composition ophtalmique pour le traitement de la maladie de l' oeil sec | |
| MA44126A (fr) | Méthodes de traitement de maladies et troubles pulmonaires | |
| MA48996A (fr) | Méthodes de traitement de maladies neurodégénératives | |
| IL269302A (en) | Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating ire1-related diseases and disorders | |
| MA46061A (fr) | Traitement ascaroside de maladies auto-immunes et inflammatoires | |
| ZA202003407B (en) | Compounds for treatment of diseases related to dux4 expression | |
| MA42930A (fr) | Traitement de maladies neurodégénératives | |
| IL281773A (en) | Eye preparation for the treatment of dry eye disease | |
| MA49059A (fr) | Traitement des cancers positifs à her2 | |
| MA41462A (fr) | Méthode de traitement de maladies | |
| ZA202101587B (en) | Protein for treatment of inflammatory diseases | |
| MA53568A (fr) | Médicaments pour le traitement de maladies ophtalmiques | |
| DK3548061T3 (da) | Behandling af neurologiske sygdomme | |
| MA53986A (fr) | Traitement de maladies neurologiques avec du zilucoplan | |
| MA54077A (fr) | Polythérapie pour le traitement de maladies hématologiques | |
| MA42287A (fr) | Traitement de patients atteints de diabète sucré de type 2 | |
| MA53817A (fr) | Composés biphényl-sulfonamide destinés au traitement de maladies du collagène de type iv | |
| MA39950A (fr) | Dérivé de 2-acylaminothiazole pour le traitement des maladies des voies urinaires et de la vessie | |
| SG10202110804WA (en) | Methods of preventing or treating ophthalmic diseases | |
| EP3606522C0 (fr) | Nouveau traitement de maladies mitochondriales | |
| MA41782A (fr) | Traitement de patients atteints de diabète de type 2 | |
| GB201805100D0 (en) | Treatment of sarcopenic diseases |